文献速递眼底病与葡萄膜炎

深度学习量化糖尿病黄斑水肿液体消退与视力获益:随机临床试验事后分析

Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该事后分析基于糖尿病视网膜病变临床研究网络方案T的6945份OCT扫描(570眼),用深度学习算法量化抗VEGF治疗12个月内视网膜内液(IRF)与视网膜下液(SRF)体积变化。结果显示SRF存在与较低基线视力相关,但随访中视力增益更大;阿柏西普和雷珠单抗较贝伐珠单抗更显著减少IRF体积。

要点

  • 基线SRF存在者基线BCVA更差(ETDRS 63.2 vs 66.9),但每4周视力增益更大(0.5 vs 0.4)。
  • 阿柏西普首针后IRF减少较贝伐珠单抗多79.8 nL,此后每4周多减少10.4 nL。
  • 雷珠单抗首针后IRF减少较贝伐珠单抗多75.2 nL。

核心结论

  • 深度学习自动分割显示DME中SRF存在与较低基线BCVA相关,但对抗VEGF治疗反应良好。
  • 自动化SD-OCT分析可用于临床评估治疗期间解剖学变化。

研究设计与样本

  • 随机临床试验(DRCR网络方案T)的事后分析,评估570眼(570例参与者)的6945份SD-OCT体积扫描。
  • 参与者按预设标准化方案接受阿柏西普、雷珠单抗或贝伐珠单抗治疗,联合或不联合延迟激光。
  • 使用深度学习算法分析12个月内IRF和SRF体积与BCVA的关联。

主要发现

  • 中央3 mm平均IRF体积从基线448.6 nL(95%CI 412.3-485.0)降至12个月161.2 nL(95%CI 135.1-187.4)。
  • 中央3 mm平均SRF体积从基线36.9 nL(95%CI 27.0-46.7)降至12个月4.4 nL(95%CI 1.7-7.1)。
  • 基线有SRF者基线BCVA ETDRS 63.2(95%CI 60.2-66.1,约Snellen 20/63),无SRF者66.9(95%CI 65.7-68.1,约20/50),P < .001。
  • 调整基线BCVA后,基线有SRF者每4周ETDRS增益0.5(95%CI 0.3-0.8),无SRF者0.4(95%CI 0.3-0.5),P = .02。
  • 阿柏西普首针后IRF减少较贝伐珠单抗多79.8 nL(95%CI 5.3-162.5,P < .001),此后每4周多减少10.4 nL(95%CI 0.7-20.0,P = .004)。

关键数值与推荐

  • 基线有SRF者基线BCVA ETDRS 63.2(约20/63),无SRF者66.9(约20/50),P < .001。
  • 基线有SRF者每4周ETDRS增益0.5,无SRF者0.4,P = .02。
  • 阿柏西普首针后IRF减少较贝伐珠单抗多79.8 nL(P < .001),每4周多减少10.4 nL(P = .004)。
  • 雷珠单抗首针后IRF减少较贝伐珠单抗多75.2 nL(P < .001)。

临床怎么用

  • 临床可借助深度学习自动分割SD-OCT液体评估DME治疗中的解剖学变化。
  • 基线SRF存在提示视力较差但抗VEGF治疗后视力增益可能更好。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Large amounts of optical coherence tomographic (OCT) data of diabetic macular edema (DME) are acquired, but many morphologic features have yet to be identified and quantified. OBJECTIVE: To examine the volumetric change of intraretinal fluid (IRF) and subretinal fluid (SRF) in DME during anti-vascular endothelial growth factor treatment using deep learning algorithms. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis of a randomized clinical trial, the Diabetic Retinopathy Clinical Research Network (protocol T), assessed 6945 spectral-domain OCT volume scans of 570 eyes from 570 study participants with DME. The original trial was performed from August 21, 2012, to October 18, 2018. This analysis was performed from December 7, 2017, to January 15, 2020. INTERVENTIONS: Participants were treated according to a predefined, standardized protocol with aflibercept, ranibizumab, or bevacizumab with or without deferred laser. MAIN OUTCOMES AND MEASURES: The association of treatment with IRF and SRF volumes and best-corrected visual acuity (BCVA) during 12 months using deep learning algorithms. RESULTS: Among the 570 study participants (302 [53%] male; 369 [65%] white; mean [SD] age, 43.4 [12.6] years), the mean fluid volumes in the central 3 mm were 448.6 nL (95% CI, 412.3-485.0 nL) of IRF and 36.9 nL (95% CI, 27.0-46.7 nL) of SRF at baseline and 161.2 nL (95% CI, 135.1-187.4 nL) of IRF and 4.4 nL (95% CI, 1.7-7.1 nL) of SRF at 12 months. The presence of SRF at baseline was associated with a worse baseline BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) score of 63.2 (95% CI, 60.2-66.1) (approximate Snellen equivalent of 20/63 [95% CI, 20/50-20/63]) in eyes with SRF vs 66.9 (95% CI, 65.7-68.1) (approximate Snellen equivalent, 20/50 [95% CI, 20/40-20/50]) without SRF (P < .001) and a greater gain in ETDRS score (0.5; 95% CI, 0.3-0.8) every 4 weeks during follow-up in eyes with SRF at baseline vs 0.4 (95% CI, 0.3-0.5) in eyes without SRF at baseline (P = .02) when adjusted for baseline BCVA. Aflibercept was associated with greater reduction of IRF volume compared with bevacizumab after the first injection (difference, 79.8 nL; 95% CI, 5.3-162.5 nL; P < .001) and every 4 weeks thereafter (difference, 10.4 nL; 95% CI, 0.7-20.0 nL; P = .004). Ranibizumab was associated with a greater reduction of IRF after the first injection compared with bevacizumab (difference, 75.2 nL; 95% CI, 1.4-154.7 nL; P < .001). CONCLUSIONS AND RELEVANCE: Automated segmentation of fluid in DME revealed that the presence of SRF was associated with lower baseline BCVA but with good response to anti-vascular endothelial growth factor therapy. These automated spectral-domain OCT analyses may be used clinically to assess anatomical change during therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01627249.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Roberts PK, Vogl WD, Gerendas BS, et al. Quantification of Fluid Resolution and Visual Acuity Gain in Patients With Diabetic Macular Edema Using Deep Learning: A Post Hoc Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32722799. doi:10.1001/jamaophthalmol.2020.2457

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。